Introduction: Multiple myeloma (MM) is a currently incurable hematologic tumor with heterogeneous clinical behavior and prognosis. During the last years, survival improved due to a better understanding of MM biology and the development of novel drugs, although it still remains unsatisfactory in many cases: new drugs and treatment strategies are needed. CD38 is uniformly expressed at high levels on MM cells and, to a lesser extent, on the surface of normal hematopoietic and non-hematopoietic cells, making this molecule an interesting target for immunotherapeutic approaches. Areas covered: This review discusses the preclinical and clinical experience on different immunotherapeutic agents targeting CD38 in MM. Expert commentary: Monoclonal antibodies (mAbs) targeting CD38 are currently changing the treatment scenario in MM, allowing physicians to reach unprecedented results, especially when anti-CD38 mAbs are used in combination with consolidated MM treatments. Other immunotherapies targeting CD38–such as conjugated anti-CD38 mAbs, bispecific antibodies stimulating T cells to eliminate CD38+ MM cells, and CD38-specific chimeric antigen receptor T cells–are interesting strategies, currently at earlier developmental stages.

CD38 as an immunotherapeutic target in multiple myeloma

Bonello F.
Co-first
;
D'Agostino M.
Co-first
;
Moscvin M.;Cerrato C.;Boccadoro M.;Gay F.
Last
2018

Abstract

Introduction: Multiple myeloma (MM) is a currently incurable hematologic tumor with heterogeneous clinical behavior and prognosis. During the last years, survival improved due to a better understanding of MM biology and the development of novel drugs, although it still remains unsatisfactory in many cases: new drugs and treatment strategies are needed. CD38 is uniformly expressed at high levels on MM cells and, to a lesser extent, on the surface of normal hematopoietic and non-hematopoietic cells, making this molecule an interesting target for immunotherapeutic approaches. Areas covered: This review discusses the preclinical and clinical experience on different immunotherapeutic agents targeting CD38 in MM. Expert commentary: Monoclonal antibodies (mAbs) targeting CD38 are currently changing the treatment scenario in MM, allowing physicians to reach unprecedented results, especially when anti-CD38 mAbs are used in combination with consolidated MM treatments. Other immunotherapies targeting CD38–such as conjugated anti-CD38 mAbs, bispecific antibodies stimulating T cells to eliminate CD38+ MM cells, and CD38-specific chimeric antigen receptor T cells–are interesting strategies, currently at earlier developmental stages.
18
12
1209
1221
https://www.tandfonline.com/doi/abs/10.1080/14712598.2018.1544240?journalCode=iebt20
https://doi.org/10.1080/14712598.2018.1544240
bispecific antibodies; CAR T cells; CD38; drug conjugates; monoclonal antibodies; multiple myeloma; ADP-ribosyl Cyclase 1; Animals; Antibodies, Bispecific; Antibodies, Monoclonal; Hematologic Neoplasms; Humans; Immunotherapy; Membrane Glycoproteins; Molecular Targeted Therapy; Multiple Myeloma; T-Lymphocytes
Bonello F.; D'Agostino M.; Moscvin M.; Cerrato C.; Boccadoro M.; Gay F.
File in questo prodotto:
File Dimensione Formato  
[Publisher Version] Bonello et al - 2018 - CD38 as an immunotherapeutic target in multiple myeloma.pdf

Accesso riservato

Descrizione: [Restricted access - Published vsn.] Bonello F, D'Agostino M, et al. Expert Opin Biol Ther. 2018 Dec;18(12):1209-1221. doi: 10.1080/14712598.2018.1544240. Epub 2018 Nov 13. © 2018 Informa UK Limited, trading as Taylor & Francis Group. Available at: https://www.tandfonline.com/doi/abs/10.1080/14712598.2018.1544240?journalCode=iebt20 | https://doi.org/10.1080/14712598.2018.1544240
Tipo di file: PDF EDITORIALE
Dimensione 1.44 MB
Formato Adobe PDF
1.44 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
[Author Vsn] Bonello F D'Agostino M et al - 2018 - Expert Opin Biol Ther - Review CD38.pdf

Accesso aperto

Descrizione: [Restricted access - Author vsn.] Bonello F, D'Agostino M, et al. Expert Opin Biol Ther. 2018 Dec;18(12):1209-1221. doi: 10.1080/14712598.2018.1544240. Epub 2018 Nov 13. © 2018 Informa UK Limited, trading as Taylor & Francis Group. The published version is available at: https://www.tandfonline.com/doi/abs/10.1080/14712598.2018.1544240?journalCode=iebt20 | https://doi.org/10.1080/14712598.2018.1544240
Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 829.02 kB
Formato Adobe PDF
829.02 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/1732886
Citazioni
  • ???jsp.display-item.citation.pmc??? 10
  • Scopus 20
  • ???jsp.display-item.citation.isi??? 18
social impact